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Regardless of etiology, inﬂammatory conditions are character-
ized by overexpression of inducible nitric oxide synthase (iNOS)
and overproduction of nitric oxide and reactive nitrogen species
(NO/RNS) in epithelial and inﬂammatory cells at the site of
carcinogenesis.
NO/RNS produced in inﬂamed tissues can contribute to the
process of carcinogenesis by different mechanisms. One of these
mechanisms is NO-dependent stimulation of genomic instability
by inhibiting of Breast Cancer type 1 Susceptibility protein
(BRCA1) expression. Block of BRCA1 expression shifts DNA dou-
ble-strand breaks (DSB) repair from error-free high-ﬁdelity homo-
logous recombination repair (HRR) to error-prone nonhomologous
end joining (NHEJ).
BRCA1 epigenetically block miRNA-155 expression via its
association with HDAC2, which deacetylates histones H2A and
H3 on the miRNA-155 promoter. The miRNA-155 is responsible for
post-translational silencing of essential members of mismatch
repair (MMR) core: MSH2, MSH6, and MLH1 proteins. They
epigenetic inactivation induces DNA microsatellite instability
(MSI). Recently, we demonstrated NO-dependent downregulation
of MMR core proteins (MSH2, MSH6, and MLH1) through the
↓BRCA1/↑miRNA-155 signaling pathway. Hence, another NO-
dependent mechanism of genomic instability is downregulation
of MMR core proteins and stimulation of the DNA MSI.
Loss or inhibition of Poly(ADP-ribose) polymerase 1 (PARP1)
activity results in accumulation of DNA single-strand breaks,
which are subsequently converted to DSB by the transcription
machinery. In BRCA-positive cells, DSB are repaired by HRR, but
they cannot be properly repaired in BRCA1-deﬁcient cells, leading
to genomic instability, chromosomal rearrangements, and cell
death. Our data demonstrated that combination of NO-donors
with PARP inhibitors signiﬁcantly sensitized the BRCA1-positive
cancer cells to DNA-damaging agents.
http://dx.doi.org/10.1016/j.redox.2015.09.013
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Background: The RAS family of small GTPases is comprised of
HRAS, NRAS, and KRAS. KRAS is invariably oncogenically mutated in
pancreatic cancers, which is known to induce this disease. Beyond
oncogenic KRAS, redox-dependent reactions have been implicated
in the activation of the remaining wild-type RAS proteins in
pancreatic cancer cell lines. These results suggest a possible
involvement of wild-type RAS proteins in pancreatic cancer.
Aims: To evaluate the impact of genetically suppressing wild-type
RAS expression on pancreatic cancer.
Methods: Hras homozygous null mice (Hras-/-) were crossed into a
Pdx-Cre; LSL-KrasG12D/+ (KC) murine background in which onco-
genic Kras is activated in the pancreas to promote preinvasive
pancreatic cancer. Tumor burden was then measured at different
stages of disease.
Results: HRas-/-;KC mice exhibited more precancerous lesions in
the pancreas and more off-target skin papillomas compared to
their wild-type counterparts, suggesting that Hras suppresses
early oncogenic Kras-driven tumorigenesis, possibly at the time
of initiation. Loss of Hras also reduced the survival of mice
engineered to develop aggressive pancreatic cancer by the addi-
tional disruption of one allele of the tumor suppressor p53
(Trp53R172H/+). However, this survival advantage was lost when
both alleles of Trp53were mutated, suggesting that wild-type Hras
inhibits tumorigenesis in a p53-dependent fashion.
Conclusions: Loss of wild-type Hras promotes the earliest stages of
pancreatic tumorigenesis, and moreover results in more rapid
progression of the disease. As such, mechanisms leading to
activation of wild-type Ras proteins, including but not limited to
redox-dependent reactions, may inﬂuence the development of
pancreatic cancer.
http://dx.doi.org/10.1016/j.redox.2015.09.014
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Background: The Ras family of small GTPases cycle between an
inactive, GDP-bound state and an active, GTP-bound state. When
bound to GTP, Ras engages and activates a number of effectors that
mediate proliferative and survival signals. Ras is mutated in over
30% of human cancers, usually at codons 12, 13, or 61, to remain in
this active, GTP-bound state, which promotes tumorigenesis. One
of these oncogenic mutations that commonly occurs in lung
cancer is G12C. Recently, it was shown that alkylating agents that
react with the thiol functional group of this mutant amino acid can
inactivate oncogenic RasG12C.
Aims: Given that Cys12 of RasG12C is accessible to thiol alkylating
agents and forms interactions within the electrostatic phosphoryl-
binding loop of Ras, we postulated that Cys12 may possess an
altered pKa, potentially allowing this residue to be modiﬁed by NO
and other cellular oxidants.
Methods: We conducted several biochemical analyses to deter-
mine whether nitrosylation of RasG12C alters its activity and
structure in vitro. We also determined the biological effects of
increasing NO production on the tumorigenic growth of cells
transformed by RasG12C.
Results: We found that Cys12 has a depressed pKa of 7.4, which
increases the susceptibility of the thiol to modiﬁcation by oxida-
tion or nitrosylation at physiological pH. We also found that
coexpressing active eNOSS1177D and RasG12C accelerated tumori-
genic growth of human and murine cell line xenografts.
Conclusion: Modiﬁcation of Cys12 in mutant, oncogenic RasG12C
may promote its tumorigenic activity.
http://dx.doi.org/10.1016/j.redox.2015.09.015
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